Brown Advisory Inc. Boosts Stake in Establishment Labs Holdings Inc. (NASDAQ:ESTA)

Brown Advisory Inc. lifted its stake in Establishment Labs Holdings Inc. (NASDAQ:ESTA – Get Rating) by 0.4% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,638,123 shares of the company’s stock after purchasing an additional 6,300 shares during the period. Brown Advisory Inc. owned 6.77% of Establishment Labs worth $110,394,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of ESTA. Rice Hall James & Associates LLC boosted its holdings in shares of Establishment Labs by 3.1% during the 1st quarter. Rice Hall James & Associates LLC now owns 34,452 shares of the company’s stock valued at $2,322,000 after purchasing an additional 1,039 shares during the last quarter. New York State Common Retirement Fund increased its position in shares of Establishment Labs by 65.5% during the first quarter. New York State Common Retirement Fund now owns 15,644 shares of the company’s stock worth $1,054,000 after acquiring an additional 6,189 shares during the period. Mount Yale Investment Advisors LLC purchased a new position in Establishment Labs during the first quarter valued at approximately $219,000. SG Americas Securities LLC purchased a new position in Establishment Labs during the first quarter valued at approximately $202,000. Finally, Assenagon Asset Management S.A. boosted its stake in Establishment Labs by 39.8% in the first quarter. Assenagon Asset Management S.A. now owns 106,479 shares of the company’s stock valued at $7,176,000 after acquiring an additional 30,317 shares in the last quarter. 77.79% of the stock is currently owned by hedge funds and other institutional investors.

Establishment Labs Stock Up 5.1 %

NASDAQ:ESTA opened at $64.56 on Friday. The company has a current ratio of 3.01, a quick ratio of 2.23 and a debt-to-equity ratio of 1.10. The company’s 50-day moving average is $57.42 and its two-hundred day moving average is $60.02. Establishment Labs Holdings Inc. has a 1-year low of $46.93 and a 1-year high of $93.80.

Establishment Labs (NASDAQ:ESTA – Get Rating) last announced its earnings results on Monday, May 9th. The company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.42) by $0.18. Establishment Labs had a negative net margin of 29.77% and a negative return on equity of 70.10%. The firm had revenue of $38.45 million for the quarter, compared to the consensus estimate of $35.40 million. During the same period in the prior year, the firm earned ($0.29) EPS. As a group, equities analysts anticipate that Establishment Labs Holdings Inc. will post -1.32 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently commented on ESTA shares. BTIG Research lowered their price objective on shares of Establishment Labs from $105.00 to $90.00 and set a “buy” rating for the company in a research note on Friday, June 24th. Cowen lifted their price objective on shares of Establishment Labs from $95.00 to $125.00 in a report on Friday, April 22nd. Finally, Cowen lifted their price objective on shares of Establishment Labs from $95.00 to $125.00 in a report on Friday, April 22nd.

Insider Activity

In other Establishment Labs news, major shareholder Jw Asset Management, Llc purchased 5,000 shares of the firm’s stock in a transaction that occurred on Friday, May 13th. The stock was purchased at an average price of $54.83 per share, for a total transaction of $274,150.00. Following the purchase, the insider now directly owns 3,192,485 shares in the company, valued at $175,043,952.55. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 13.08% of the company’s stock.

Establishment Labs Company Profile

(Get Rating)

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under Motiva Implants brand name. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander, as well as distributes Puregraft line of products for autologous adipose tissue harvesting and redistribution.